Truist analyst Samuel Brodovsky raised the firm’s price target on OrthoPediatrics to $39 from $35 and keeps a Buy rating on the shares as part of a broader research note, turning more positive on the MedTech industry heading into FY24. The firm is citing dwindling recession fears, a downward interest rate bias/perception, a “more pragmatic” view toward the GLP1 overhang/impact, and an attractive sector growth profile for MedTech next year. After a “tough” 2023 in healthcare, MedTech could be a relative destination for funds within healthcare and even “inter-sector” as a “beta/growth” segment that underperformed, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on KIDS:
- OrthoPediatrics price target lowered to $50 from $60 at JMP Securities
- OrthoPediatrics announces launch of specialty bracing division
- OrthoPediatrics Corp. Announces Launch of Specialty Bracing Division
- OrthoPediatrics Corp. to Host Educational and Networking Events at 19th Annual International Pediatric Orthopaedic Symposium (IPOS)
- OrthoPediatrics backs FY23 revenue view $148M-$151M, consensus $149.17M